OPKO Health, Inc. (OPK)
NASDAQ: OPK · Real-Time Price · USD
1.190
-0.090 (-7.03%)
Aug 1, 2025, 4:00 PM - Market closed
Exscientia Revenue
OPKO Health had revenue of $156.81M in the quarter ending June 30, 2025, a decrease of -13.93%. This brings the company's revenue in the last twelve months to $664.03M, down -7.31% year-over-year. In the year 2024, OPKO Health had annual revenue of $713.14M, down -17.41%.
Revenue (ttm)
$664.03M
Revenue Growth
-7.31%
P/S Ratio
1.24
Revenue / Employee
$221,565
Employees
2,997
Market Cap
944.60M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 713.14M | -150.35M | -17.41% |
| Dec 31, 2023 | 863.50M | -140.70M | -14.01% |
| Dec 31, 2022 | 1.00B | -770.52M | -43.42% |
| Dec 31, 2021 | 1.77B | 339.31M | 23.64% |
| Dec 31, 2020 | 1.44B | 533.48M | 59.15% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
OPK News
- 3 days ago - OPKO Health, Inc. (OPK) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results - GlobeNewsWire
- 4 weeks ago - NextPlat Issues Interim CEO Update Shareholder Letter - PRNewsWire
- 5 weeks ago - OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium - GlobeNewsWire
- 2 months ago - OPKO Health to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - OPKO Health, Inc. (OPK) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program - GlobeNewsWire
- 4 months ago - OPKO and Entera partner to develop obesity pill - Reuters